Supplementary Material for: The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives

Aspirin and other non-steroidal anti-inflammatory

drugs (NSAIDs) have received considerable interest as

potential chemopreventive agents. The aim of this review

is to summarize the accumulated knowledge on

the effect of NSAIDs on breast cancer incidence and

natural history, and the underlying pathophysiology.

NSAIDs mainly block inflammation by inhibiting cyclooxygenase

enzymes, leading to lower prostaglandin

synthesis. The latter has been reported to affect breast

cancer risk through hormonal and inflammation-related

pathways. Intensity, dose, frequency, duration,

and timing of administration may also be significant.

There is currently enough evidence to support a role of

NSAIDs in breast cancer prevention and relapse, which

deserves further large-scale experimental and clinical

investigation.